Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

Researchers from MIT and Dana-Farber Cancer Institute have discovered that a class of peptides expressed in pancreatic cancer ...

Cryptic peptides, which are expressed in pancreatic cancer cells, could be promising targets for T-cell therapies that attack pancreatic tumors, according to a new study.

JNJ-1900 (NBTXR3), a novel, potentially first-in-class oncology therapy, demonstrated a median overall survival of 23 months ...

Researchers from MIT and Dana-Farber Cancer Institute have discovered that a class of peptides expressed in pancreatic cancer ...

Nanobiotix has presented complete outcomes from the dose escalation and dose expansion phases of the Phase I trial of ...

Pancreatic cancer remains one of the most formidable oncological challenges of our time. Known for its late detection and rapid progression, it ranks as the seventh leading cause of cancer-related ...

Most pancreatic cancer patients receive a combination of surgery, radiation treatment, and chemotherapy. Immunotherapy treatments such as checkpoint blockade inhibitors, which are designed to help ...

Researchers analyzed DNA from pancreatic cancer patients and found that FUT2 and FUT3 genotypes ... initially classified as inoperable (before receiving chemotherapy or radiation treatment). The TMGM ...

Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall ...

Researchers analyzed DNA from pancreatic cancer patients and found that ... as inoperable (before receiving chemotherapy or radiation treatment). The TMGM had approximately 15% more accuracy ...